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NF-κB-dependent and -independent epigenetic
modulation using the novel anti-cancer agent DMAPT
H Nakshatri*,1,2, HN Appaiah1, M Anjanappa1, D Gilley3, H Tanaka3, S Badve4, PA Crooks5, W Mathews6, C Sweeney7
and P Bhat-Nakshatri1
The transcription factor nuclear factor-kappaB (NF-κB) is constitutively active in several cancers and is a target of therapeutic
development. We recently developed dimethylaminoparthenolide (DMAPT), a clinical grade water-soluble analog of parthenolide,
as a potent inhibitor of NF-κB and demonstrated in vitro and in vivo anti-tumor activities in multiple cancers. In this study, we show
DMAPT is an epigenetic modulator functioning in an NF-κB-dependent and -independent manner. DMAPT-mediated NF-κB
inhibition resulted in elevated histone H3K36 trimethylation (H3K36me3), which could be recapitulated through genetic ablation of
the p65 subunit of NF-κB or inhibitor-of-kappaB alpha super-repressor overexpression. DMAPT treatment and p65 ablation
increased the levels of H3K36 trimethylases NSD1 (KMT3B) and SETD2 (KMT3A), suggesting that NF-κB directly represses their
expression and that lower H3K36me3 is an epigenetic marker of constitutive NF-κB activity. Overexpression of a constitutively
active p65 subunit of NF-κB reduced NSD1 and H3K36me3 levels. NSD1 is essential for DMAPT-induced expression of
pro-apoptotic BIM, indicating a functional link between epigenetic modification and gene expression. Interestingly, we observed
enhanced H4K20 trimethylation and induction of H4K20 trimethylase KMT5C in DMAPT-treated cells independent of NF-κB
inhibition. These results add KMT5C to the list NF-κB-independent epigenetic targets of parthenolide, which include previously
described histone deacetylase 1 (HDAC-1) and DNA methyltransferase 1. As NSD1 and SETD2 are known tumor suppressors and
loss of H4K20 trimethylation is an early event in cancer progression, which contributes to genomic instability, we propose DMAPT
as a potent pharmacologic agent that can reverse NF-κB-dependent and -independent cancer-specific epigenetic abnormalities.
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Epigenetics is defined as heritable changes in gene expres-
sion mediated mostly by DNA methylation and histone tail
modifications without changes in DNA sequence.1 Epigenetic
abnormalities in cancer lead to reprogramming of gene
expression resembling embryonic stem cells, loss of tumor
suppressors, or reactivation of oncofetal genes.2,3 For
example, enhanced histone 3 lysine 27 trimethylation
(H3K27me3), mediated by a complex of proteins, including
the histone methyltransferase EZH2, causes the silencing of
tumor-suppressor genes.4,5
Similar to H3K27me3, histone 3 lysine 36 trimethylation
(H3K36me3) has a diverse role in chromatin structure and
function.6 H3K36me3 regulates transcription of active euchro-
matin, alternative splicing, DNA repair, and transmission of the
memory of gene expression from parents to offspring.7 At least
eight enzymes methylate H3K36. Nuclear receptor-binding
SET domain protein 1 (NSD1; lysine methyltransferases 3B
(KMT3B)) and NSD2 are involved in monomethylation and
dimethylation, whereas SET domain containing 2 (SETD2;
KMT3A) trimethylates H3K36.6 However, depletion of NSD1 in
certain cells leads to loss of H3K36me3 and altered gene
expression.8,9
NSD1 functions as a tumor suppressor in several cancers.
For example, epigenetic silencing of NSD1 is observed in
neuroblastoma.9 NSD1 mutation/deletion is observed in
bladder cancer.10 NSD1 is one of the genes essential for
anti-estrogen sensitivity in breast cancer.11 NSD1 is also
described as an oncogene in acute myeloid leukemia in which
a chromosomal translocation creates nucleoporin 98 kDa
(NUP98):NSD1 fusion protein, and the expression is driven
by NUP98 regulatory elements.12 NSD2 is an oncogene,
whereas SETD2 is inactivated through mutation/deletion in
multiple cancers.10,13,14 Interestingly, H3K36me3 and
H3K27me3 on a gene may be mutually exclusive, suggesting
distinct role of modulators of these modifications on gene
expression.15
Loss of histone 4 lysine 20 trimethylation (H4K20me3) is a
hallmark of cancer.16 The histone methyltransferases KMT5B
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(SUV4-20H1) and KMT5C (SUV4-20H2) mediate histone
H4K20me3, whereas PHD finger protein 2 (PHF2) demethy-
lates this residue.17,18 NSD1 is also reported to trimethylate
H4K20.9 H4K20me3 is necessary for the repressive pathway
that induce pericentric heterochromatin required for G2/M
arrest in response to DNA damage and recruitment of DNA
repair complex.17,19 In addition, loss of H4K20me3 is
associated with telomere elongation and derepression of
telomere recombination.20 Depletion of KMT5B or KMT5C
leads to increased telomere elongation, which is common in
cancer.20
Developing drugs that reverse cancer-specific histone
modifications is one of our goals. Towards this end, we
targeted the transcription factor nuclear factor-kappaB (NF-κB),
which is activated in cancers and regulates inflammation-
associated epigenetic changes.21,22 Using pharmacological
and genomic approaches, we show upregulation of NSD1 and
SETD2 upon NF-κB inhibition. Dimethylaminoparthenolide
(DMAPT), the pharmacological inhibitor of NF-κB, additionally
increased KMT5C and H4K20me3 independent of its NF-κB
inhibition attribute.
Results
The effects of DMAPT on histone modifications. Parthe-
nolide, an NF-κB inhibitor, reduces histone deacetylase 1
(HDAC-1) and DNA methyltransferase 1 independent of NF-κB
inhibition.23,24 However, it is unclear whether parthenolide
alters NF-κB-dependent epigenetic changes that are
observed in inflammation.22 To test this possibility, we
examined the effect of dimethylaminoparthenolide (DMAPT),
a water-soluble analog of parthenolide,25 on the expression
of histone-modifying enzymes and on histone modifications.
The study was initiated in bladder cancer cell lines UMUC-3
and RT-4 because of our previous report showing DMAPT-
mediated cell cycle arrest and apoptosis of UMUC-3 cells
in vitro and inhibition of tumor growth in xenograft models.25
DMAPT reduced the levels of HDAC-1 in UMUC-3 cells but
had a modest effect in RT-4 cells (Figure 1a). DMAPT
reduced EZH2 and C-terminal-binding protein 1 (CtBP1)
more efficiently in UMUC-3 cells compared with RT-4 cells.
In contrast, the effect of DMAPT on poly-(ADP-ribose)
polymerase (PARP)-1 was more pronounced in RT-4 cells.
These changes in histone-modifying enzyme levels corre-
lated with an increase in the levels of p21 and pro-apoptotic
BIM (Figure 1b). It is unlikely that the effect of DMAPTon the
above proteins is due to genotoxic stress/DNA-damage
response, because DMAPT did not alter TIP60 (histone
acetyltransferase Tip60) levels, which is typically activated
upon double-stranded DNA break26 (Figure 1a).
We next determined the effects of DMAPT on histone H3
and H4 modifications. DMAPT increased the levels of
H3K36me3 by 1.6–2.5-fold, although the induction was
transient in UMUC-3 cells (Figure 1c). Increase in
H3K36me3 was accompanied with decrease in H3K27me3
in RT-4 cells only, despite DMAPT reducing EZH2 levels in
both cell types. Overall, DMAPT displayed higher effect on
epigenetic machinery in RT-4 cells compared with
UMUC-3 cells.
With respect to histone H4, DMAPT increased
H4K20me3 by 2.8–16-fold (Figure 1c). H4K8 acetylation
was modestly lower in DMAPT-treated cells, although this
change was observed only after 24 h of treatment. H4K8
acetylation is usually an inflammatory response mediated
by NF-κB, and the effect of DMAPT on this acetylation
is consistent with its ability to inhibit NF-κB.27 Among
various histone modifications examined, H3K36me3
and H4K20me3 were consistently elevated in DMAPT-
treated cells.
NF-κB inhibition through genomic approaches results in
elevated H3K36me3. We used two model systems to
determine which among the activities of DMAPT described
above can be recapitulated through genomic inhibition of
NF-κB. The first model system involved overexpression
of inhibitor-of-kappaB alpha super-repressor (IκBαSR), and
the second approach utilized mouse embryonic fibroblasts
(MEFs) lacking the p65 subunit of NF-κB.28,29 Unfortunately,
UMUC-3 cells overexpressing IκBαSR could not be main-
tained for a prolonged time. We had previously demonstrated
feasibility of generating MDA-MB-231 breast cancer cells
overexpressing IκBαSR.28 MDA-MB-231 cells have constitu-
tively active NF-κB, and IκBαSR reduced basal and tumor
necrosis factor alpha (TNFα)-inducible activation of NF-κB
(Figure 2a). P65− /− MEFs lack p65 DNA-binding activity
but displayed p50 and c-Rel DNA-binding activity as evident
from antibody supershift assay (Figure 2a, compare lanes 6
with 8, 15 with 19, and 12 with 20).
Basal H3K36me3 was 1.8-fold higher in IκBαSR cells
compared with parental cells, which coincided with lower
H3K36 dimethylation (Figure 2b). These results suggest
that NF-κB inhibition through genomic approaches can
recapitulate the effects of DMAPT on H3K36me3. The effect
of DMAPT on H4K20me3 in MDA-MB-231 cells was not as
robust as in UMUC-3 cells, suggesting cell type specificity
(Figure 2b).
We next examined wild-type and p65− /− MEFs for histone
modifications. Basal H3K36me3 was 2-fold higher in p65− /−
cells compared with wild-type cells (Figure 2c). Interestingly,
DMAPT significantly increased H4K20me3 in wild-type but not
in p65− /− cells. In addition, basal H4K20me3 levels were the
same in wild-type and p65− /− cells. Reasons for this
discrepancy are unknown.
DMAPT treatment or NF-κB inhibition results in elevated
NSD1 and SETD2. To determine the targets of DMAPT that
are responsible for histone H3K36me3, we measured the
levels of NSD1, NSD2, and SETD2. DMAPT increased the
expression of NSD1 in both RT-4 and UMUC-3 cells
(Figure 3a). Highest induction was observed in RT-4 cells
(2.6-fold), which also showed persistent elevation of
H3K36me3 upon DMAPT treatment.
To obtain definitive evidence for the negative regulation of
NSD1 expression by NF-κB, we measured NSD1 in MDA-
MB-231 cells overexpressing IκBαSR and p65− /− MEFs.
DMAPT increased NSD1 in MDA-MB-231 and wild-type
MEFs although the level of induction was not as high as in
RT-4 cells (Figure 3a). Basal expression of NSD1 was 2.1-
fold higher in p65− /− cells compared with wild-type cells
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confirming that inhibition of canonical NF-κB results in
elevated NSD1. DMAPT treatment or IκBαSR overexpres-
sion had negligible effect on NSD2 levels (Supplementary
Figure S1A).
Similar to NSD1, SETD2 was responsive to DMAPT
treatment or NF-κB inhibition through genomic approaches,
although the degree of response was lower and was cell
type-specific (Figure 3b). Critically, basal SETD2 levels were
Figure 1 The effect of DMAPTon the expression of epigenetic regulators and on histones. (a) DMAPTreduced the levels of EZH2, HDAC-1, CtBP1, and PARP1 in a cell type-
dependent manner. Cells were treated with 10 μM DMAPT for the indicated time, and cell lysates were subjected to western blotting. Representative data from two or more
experiments are shown. (b) DMAPT induced the expression of p21 and BIM. (c) The effect of DMAPT treatment on histone modifications. H3K36me3 blots were reprobed with
histone H4 as a quality control
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Figure 2 The role of NF-κB in DMAPT-mediated histone modifications. (a) NF-κB DNA-binding activity in MDA-MB-231 with or without IκBαSR overexpression and in MEFs
with and without p65 deletion. Cells were incubated with or without TNFα for 15 min, and NF-κB and SP-1 (as a control) DNA-binding activity was measured by electrophoretic
mobility gel shift assay. Antibody supershift assay with extracts from wild-type and p65− /− cells is shown in the right side (lanes 13–20). (b) The effect of IκBαSR
overexpression on DMAPT-induced histone modification in MDA-MB-231 cells. Basal H3K36me3 was higher in cells with IκBαSR overexpression compared with parental cells
with empty lentivirus (pCL6), and it was further increased by DMAPT. (c) P65− /− MEFs showed elevated basal H3K36me3 but not H4K20me3 compared with wild-type MEFs.
DMAPT increased H3K36me3 and H4K20me3 in wild-type MEFs
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Figure 3 DMAPT induced histone H3K36 methyltransferases NSD1 and SETD2. (a) The effect of DMAPTon NSD1 expression. Cells were treated with 10 μM DMAPT for
12 h, and qRT-PCR was performed to measure NSD1 mRNA. Average± S.E.M. from biological replicates is shown. Asterisk in this and subsequent figures denotes statistically
significant differences with a P-value ofo0.05. (b) The effect of DMAPTon SETD2 expression. Basal SETD2 level was significantly higher in p65− /− cells compared with wild-
type cells. (c) The effect of DMAPTon NSD1 and SETD2 proteins in wild-type and p65− /− MEFs. (d) DMAPTreduced CXCL1 mRNA in RT-4 and UMUC-3 cells. (e) The effect
of p65NLS50 expression on NSD1 and SETD2 expression in p65− /− cells. Cells were transfected with empty vector pcDNA3 or p65NLS50 vector (10 μgs), and RNA was
analyzed for NSD1 and SETD2 levels 48 h after transfection. (f) H3K36me3 and H4K20me3 levels in pcDNA3- and p65NLS50-transfected cells. Experiments were done as in
panel (e). (g) DMAPT (10 μM) reduced PARP-1 in wild-type but not p65− /− cells. (h) Wild-type but not p65− /− cells were sensitive to DMAPT-induced apoptosis. Cells were
treated with the indicated concentration of DMAPT for 24 h, and apoptosis was measured using Annexin V labeling. Representative results are shown
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higher in p65− /− cells (~2-fold) compared with wild-type
cells, demonstrating an effect of NF-κB on its expression.
To ensure that DMAPT treatment or NF-κB inhibition leads
to elevated NSD1 and SETD2 proteins, western blotting was
performed. One set of antibodies among many tested
recognized proteins of expected size (~300 kDa) and were
reactive against only murine proteins. Basal NSD1 and
SETD2 levels were higher in untreated p65− /− MEFs
compared with wild-type MEFs (Figure 3c). DMAPT increased
NSD1 protein in wild-type MEFs. In contrast, SETD2 protein
levels were higher in DMAPT-treated wild-type and p65− /−
cells. It appears that cell confluency impacts basal NSD1 and
SETD2 levels, as the basal expression was lower in untreated
cells plated for 24 h compared with cells plated for 12 h.
Although NF-κB predominantly increases the expression of
genes, it represses few genes,30–32 and this study adds NSD1
and SETD2 to the list of NF-κB repressed genes. To ensure
that induction of NSD1 and SETD2 by DMAPT is not due to a
global positive effect of DMAPTon transcription, we measured
the effect of DMAPT on the expression of NF-κB-inducible
CXCL1.33 DMAPT reduced the level of CXCL1 in both
UMUC-3 and RT-4 cells (Figure 3d), confirming the specificity
in the effects of DMAPTon NSD1 and SETD2.
To further demonstrate the negative relationship between
NF-κB and NSD1, we transfected p65− /− cells with a
constitutively active p65 subunit of NF-κB in which nuclear
localization signal of p65 has been replaced with that of p50
subunit (p65NLS50).34 P65− /− cells transfected with
p65NLS50 showed lower levels of NSD1 but not SETD2
(Figure 3e). The reason for the lack of effects of p65NLS50 on
SETD2 is unknown. H3K36me3 but not H4K20Me3 levels
were lower in p65NLS50-transfected cells compared with the
vector-transfected cells (Figure 3f), demonstrating the exis-
tence of an NF-κB:NSD1:H3K36me3 axis.
To correlate the effect of DMAPTon NSD1 and H3K36me3
on cellular phenotype, we subjected untreated and DMAPT-
treated wild-type and p65− /− MEFs to western blotting
analysis for PARP-1 and apoptosis assay using Annexin V
labeling. DMAPTreduced the levels of PARP-1 (Figure 3g) and
induced apoptosis (Figure 3h) in wild-type but not p65− /−
cells. Resistance of p65− /− cells to DMAPT-induced
apoptosis is surprising, considering that these cells have
higher basal levels of NSD1. One possibility is that, in the
absence of p65, cells adapt to alternative survival mode, and
inducible/acute suppression of NF-κB activity is required to
evoke apoptotic response. We could not efficiently reduce
NSD1 in these cells by siRNA owing to poor transfection
efficiency, which prevented us from confirming the role of
DMAPT-induced NSD1 in apoptosis.
DMAPT increases the expression of KMT5C (SUV4-20H2)
in a cell type-dependent manner. As noted in Figure 1,
DMAPT increased H4K20me3 although this induction
appeared to be NF-κB-independent, because p65− /− cells
did not display elevated levels of H4K20me3 (Figure 2).
KMT5C/SUV4-20H2 is one of the methyltransferases
involved in this trimethylation.35 DMAPT increased the
expression of KMT5C consistently in RT-4, UMUC-3, and
MDA-MB-231 cells (Figure 4a). However, there was marked
experimental variability in the effect of DMAPT on KMT5C
expression in MEFs (induction in two out of the three
experiments in wild-type but not p65− /− MEFs,
Supplementary Figure S1B). Moreover, IκBαSR overexpres-
sion in MDA-MB-231 cells did not lead to elevated KMT5C
expression. Based on these results, we conclude that
DMAPT induces KMT5C in a cell type-dependent but
NF-κB-independent manner. In this regard, DMAPT induces
c-Jun N-terminal kinase (JNK) and generates of reactive
oxygen species independent of NF-κB inhibition.25
H3K36 demethylases are not the targets of DMAPT.
Previous studies have demonstrated that lysine demethy-
lases 2A (KDM2A; FBXL11) and KDM2B (FBXL10) demethy-
late monomethylated and dimethylated H3K36, whereas
KDM4A, KDM4B, KDM4C, KDM4D, and NO66 demethylate
H3K36 dimethyl and trimethyl moieties.36 Additionally, inde-
pendent studies have demonstrated that NSD1, NF-κB, and
KDM2A form a feedback axis in which NSD1 methylates p65
subunit and activates NF-κB, which leads to elevated
expression of KDM2A.37 KDM2A in turn demethylates and
inactivates NF-κB. KDM2B is also an NF-κB-inducible
gene.38 As NF-κB inhibited NSD1 expression, we next
examined the effect of DMAPT or IκBαSR overexpression
on the expression of KDMs associated with demethylation of
Figure 4 DMAPT increased histone H4K20 trimethyltransferase KMT5C in a cell
type-dependent but NF-κB-independent manner. (a) KMT5C expression in DMAPT-
treated cells. Cells were treated with DMAPT for 6 h. Note that IκBαSR
overexpression had minimum effect on KMT5C expression in MDA-MB-231 cells.
(b) NF-κB activity is required for KDM2B expression in MDA-MB-231 but not in MEFs.
IκBαSR overexpression caused significant drop in basal KDM2B levels in MD-
MB-231 cells, whereas p65 knockout did not have an effect on its expression in MEFs
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H3K36me3. KDM2B showed a distinct pattern of expression
upon pharmacological or genetic inhibition of NF-κB
(Figure 4b). DMAPT treatment did not alter KDM2B in
MDA-MB-231 cells. However, IκBαSR overexpression
reduced its basal expression consistent with reported
NF-κB-inducible expression of this gene.38 Interestingly,
wild-type and p65− /− MEFs showed similar levels of
KDM2B and DMAPT had no effect on its expression, which
suggests cell type-specific requirement of NF-κB for its
expression. Lack of effect of DMAPT on its expression is
intriguing, which could be due to competing signaling
pathways activated/repressed by DMAPT compensating for
the loss of NF-κB activity. In this respect, we had previously
demonstrated the ability of DMAPT or parthenolide to induce
JNK independent of NF-κB inhibition.25,39 Note that IκBαSR
overexpression did not have an effect on KDM4A and
KDM4B expression, although DMAPT modestly increased
their expression, which could be an off-target effect or a non-
specific response of cells to drug treatment (Supplementary
Figure S1C). Overall, these results favor the possibility that
increase in KMTs rather than reduced levels of KDMs
contribute to H3K36 trimethylation in DMAPT-treated cells.
The effect of DMAPT treatment, IκBαSR overexpression,
or p65 deletion on epigenetic markers and the expression
of epigenetic modulators are summarized in Table 1.
NSD1 is essential for DMAPT-induced BIM expression.
To determine whether NSD1 and SETD2 have any role in
DMAPT-induced BIM and p21 expression, we examined the
effects of siRNA against NSD1 and SETD2 on their
expression in UMUC-3 cells. SiRNA against NSD1 but not
SETD2 prevented DMAPT-induced BIM and p21 expression
(Figure 5a). For unknown reason, we observed elevated
basal p21 in NSD1 siRNA-treated cells. Because of the
transfection-induced stress, we consistently observed lower
p21 and BIM induction by DMAPT under this experimental
condition. siRNAs were effective in reducing the levels of
target gene mRNAs (Figure 5b). We were unable to
reproducibly detect the effects of NSD1 and SETD2 siRNA
on basal and/or DMAPT-induced H3K36me3 (except in
MCF-7 cells) or H4K20me3.
We next examined whether NSD1 and SETD2 are required
for DMAPT-induced growth inhibition. Cells transfected with
SETD2 siRNA but not NSD1 siRNA were partially resistant to
DMAPT compared with control siRNA-transfected cells
(Figure 5c).
NSD1 and SETD2 expression in bladder and breast
cancer. Analysis of the public database cBioportal revealed
significant mutations/deletion of NSD1 and SETD2 in multiple
cancers, including bladder cancer (www.cbioportal.org).40,41
In The Cancer Genome Atlas (TCGA) bladder data set
(n=127), 8% of cases showed deletions, amplification, and/or
mutation of NSD1. One percent of breast cancers showed
NSD1 alterations (n= 482). Mutation, amplification, and/or
deletion of SETD2 were observed in 10% of bladder cancer
(n= 127). SETD2 alterations were found in 1% of breast
cancer (n=482). Across multiple cancers, most of the
SETD2 alterations involved mutations and deletions but
rarely amplification. To determine whether the expression
levels of these two genes have diagnostic/prognostic impact,
we queried public gene expression databases. In one of the
bladder cancer data set in gene expression omnibus
(GEO),42 we observed significant reduction in NSD1 expres-
sion in non-muscle invasive urothelial cancer with or without
carcinoma in situ and mucosa invasive carcinoma but not in
carcinoma in situ compared with normal urothelium
(Figure 6a). Oncomine search revealed copy number loss
and reduced mRNA levels in various bladder cancer stages
(Supplementary Figure S2). In contrast to NSD1, SETD2
expression levels did not show any correlation with disease
stage. In fact, its expression was elevated in urothelial cancer
with carcinoma in situ and mucosa invasive carcinoma but
not in carcinoma in situ cases or cancer without carcinoma
in situ compared with normal urothelium (Figure 6b). In
addition, Oncomine database search did not reveal bladder
cancer tumor stage-specific changes in SETD2 expression.
However, comparison of SETD2 expression across several
cancers demonstrated lower SETD2 expression in multiple
cancers, including bladder cancer (fold changes −2.3 and
− 3 in two studies) (Supplementary Figure S2).
We recently developed an online tool, which enables
investigators to determine the prognostic value of genes in
420 data sets with clinical annotation.43 With the TCGA
breast cancer data set, higher expression of NSD1 showed a
trend toward better overall survival when all tumor subtypes
were considered (Figure 6c) and significant survival advan-
tage in HER2-negative patients (135 high and 134 low
expression cases, Figure 6d). Elevated SETD2 expression
correlated with better overall survival in all the subtypes of
breast cancer (Figures 6e–h, ER-positive cases—229 high
and 229 low; ER-negative cases—68 high and 67 low;
HER-negative cases—135 high and 134 low). Combined
NSD1 and SETD2 expression levels correlated with better
outcome in the TCGA data set (Figure 6i) and in another public
database (247 high and 314 low expression cases,
Figure 6j).44
Discussion
In this study, we report the ability of the NF-κB inhibitor DMAPT
to elevate the expression of NSD1, SETD2, and KMT5Cand to
increase H3K36me3 and H4K20me3. Induction of NSD1,
SETD2, and H3K36me3 could be recapitulated through
genomic approaches that inhibited NF-κB. These results
reveal H3K36me3 as an epigenetic biomarker of constitutive
NF-κB activation in cancer.
Table 1 Summary of the effects of DMAPT treatment, IκBαSR overexpression,
and p65 depletion on epigenetic markers and the expression of epigenetic
regulators
DMAPT IκBαSR P65− /−
H3K36me3 Yes Yes Yes
H4K20me3 Yes No No
NSD1 Yes ?a Yes
SETD2 Yes ?a Yes
KMT5C Yes No No
KDM2B No Yes No
aTrend of an effect but did not reach statistical significance
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Impact of NSD1–NF-κB axis on cancer. Several epithelial
and hematological malignancies show constitutive NF-κB
activation, which could lead to reduction in NSD1 levels.21
Although NSD1 has been described as an oncogene in
leukemia, this oncogenic function is only in the context of
NUP98–NSD1 fusion gene where the fusion protein increases
H3K36me3 specifically at the HoxA locus and increases HoxA
expression.12 NF-κB inhibition in this context is less likely to
cause upregulation of NUP98–NSD1, because NUP98 reg-
ulatory region drives this fusion gene expression. In neuro-
blastoma, NF-κB inhibitors could potentially restore the
expression of epigenetically inactivated NSD1.9
In breast cancer, loss of NSD1 expression is associated with
resistance to anti-estrogens.11 NF-κB has a significant role in
anti-estrogen resistant growth of breast cancer cells and NF-κB
inhibitors reverse anti-estrogen resistance, which may involve
induction of NSD1.45–47 Restoration of NSD1 expression upon
DMAPT treatment could also alter sensitivity to other therapies,
because NSD1 is essential for BIM expression (Figure 5). BIM
polymorphism and BIM levels in treatment-naive cancers
determine sensitivity to receptor kinase inhibitors, particularly
EGFR and mutant B-RAF signaling pathway inhibitors,
glucocorticoids, and paclitaxel.48
NSD1 methylates and activates non-histone targets, includ-
ing the p65 subunit of NF-κB.37 However, NSD1 induction due
to NF-κB inhibition is less likely to lead to activation of NF-κB
target genes, because NF-κB is functionally inactive due to
cytoplasmic retention or degradation. NSD1 functions as a co-
activator of nuclear receptors, including retinoic acid
receptor.49 NF-κB inhibition leading to elevated NSD1 may
sensitize cancer cells to retinoic acid-induced differentiation.
Impact of SETD2 repression by NF-κB on cancer. SETD2
is frequently inactivated through mutation and/or deletion in
renal, bladder, and breast cancers.10,14,50 Lower expression
of this gene in breast tumors correlated with poor overall
survival (Figure 6). DMAPT could potentially be used to
restore the expression of SETD2 in tumors, although such a
treatment may not be an option in cases with mutation. Apart
from histones, SETD2 interacts with p53 and induces
p53-dependent pro-apoptotic genes but represses hdm2,
a p53 antagonist.51 Therefore NF-κB inhibition in tumor cells
with intact p53 may trigger a SETD2- and p53-dependent
apoptosis. In this respect, DMAPT was more effective in
inducing epigenetic changes in RT-4 cells with wild-type p53
compared with p53-mutant UMUC-3 cells.
NF-κB-mediated repression of gene expression. This
study adds to the list of growing number of genes repressed
by NF-κB. We had previously demonstrated NF-κB-mediated
repression of GADD153.30 NF-κB subunit p65, when unpho-
sphorylated at S276, recruits HDAC3 and represses
transcription.52 Additionally, NF-κB represses transcription
by targeting SP-1 and SP-3 transcription factors.32,53
Regulatory regions of NSD1 and SETD2 contain binding
sites for NF-κB and SP-1, respectively. It is possible that
unphosphorylated p65 occupies NSD1 regulatory region to
repress transcription and DMAPT treatment or deletion of p65
leads to derepression and consequent activation. Similarly,
NF-κB may target SP-1 to repress SETD2. As basal levels of
Figure 5 NSD1 is essential for DMAPT-induced BIM and p21 expression.
(a) BIM and p21 levels in untreated and DMAPT-treated UMUC-3 cells additionally
transfected with siRNA against luciferase as a negative control, NSD1, SETD2,
or both NSD1 and SETD2. Cells were treated after 3 days of siRNA transfection
with DMAPT and harvested for proteins after 24 h of DMAPT treatment.
NSD1 siRNA prevented DMAPT-induced BIM and p21. For unknown reasons,
basal p21 levels in NSD1 siRNA-treated cells showed remarkable experimental
variability in UMUC-3 cells. Densitometry values show comparison between
untreated controls and DMAPT-treated cells with respective controls normalized
to 1. (b) NSD1 and SETD2 mRNA levels in siRNA-transfected cells. Respective
mRNAs were measured 4 days after siRNA transfection. (c) SETD2 is required
for DMAPT-mediated growth inhibition. Cells were plated in a 96-well plate
and treated with DMAPT for 48 h. Cell proliferation was measured using
BrDU-incorportation ELISA
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Figure 6 Prognostic value of NSD1 and SETD2 in cancer. (a) Levels of NSD1 in normal urothelium and various stages of bladder cancer. NCBI GEO data set GDS1479,
which contains NSD1 expression levels (one probe set) in normal urothelium and different stages of bladder cancer, was used to generate this figure. (b) Levels of SETD2 in
normal urothelium and various stages of bladder cancer. Data were generated using the same data set as in panel (a) except that signals were average of three probes that
measured SETD2 mRNA. (c–j) Prognostic value of NSD1, SETD2, or combination in different subtypes of breast cancer. Public databases created by us43 (c–i) and others44
(j) were used to generate these figures
Epigenetic targets of NF-κB
H Nakshatri et al
9
Cell Death and Disease
both NSD1 and SETD2 were higher in p65− /− cells, it is
unlikely that NF-κB undergoes repressor to activator switch in
DMAPT-treated cells to cause induction of NSD1 and SETD2.
The fact that DMAPT treatment or p65 deletion did not have
global effects on histone methyltransferases or demethylases
suggests that repression of NSD1 and SETD2 is a specific
component of NF-κB-mediated epigenetic changes.
KDM6B, which demethylates H3K27, and PHF2, which
demethylates H4K20, and KDM2B, which demethylates
H3K36me1, H3K36me2, and H3K4me3, have previously been
reported as NF-κB-inducible genes.18,22,38 Although we
observed NF-κB-dependent expression of KDM2B, as its levels
were lower in IκBαSR-overexpressing cells compared with
parental cells, we did not observe an effect of DMAPTon other
KDMs tested. There are two possible explanations; one is that
NF-κB controls their expression in a cell type-dependent
manner, and the second is that NF-κB-independent activities
of DMAPT cause compensatory increase in the expression of
these demethylases, thus nullifying the effects of NF-κB
inhibition. The second possibility appears to be the case with
KDM2B. Nonetheless, these observations provide explanation
as to why results obtained using pharmacological inhibitors are
not always compatible with results of gene ablation studies.
Evaluation of the role of NSD1 and SETD2 in DMAPT-
induced BIM and p21 expression and cell death showed
discordant results. Although NSD1 was required for DMAPT-
induced BIM expression, NSD1 knockdown had minimum
affect on growth inhibition by DMAPT. In contrast, SETD2
knockdown had no effect on DMAPT-induced BIM and p21
expression, but cells were partially resistant to DMAPT-
mediated growth inhibition. At present, SETD2 downstream
targets that mediate DMAPT-induced cell growth inhibition in
p53-mutant cells are unknown.51 Despite gaps in our under-
standing of this aspect of DMAPTaction, data presented here
suggest that NSD1 and SETD2 along with H3K36me3 can be
used as biomarkers to measure the therapeutic activity of
DMAPTas well as any other drugs that inhibit NF-κB activity.
Materials and Methods
Cell lines. UMUC-3 cells and MDA-MB-231 cells were maintained in MEM with
10% fetal bovine serum (FBS). RT-4 cells were maintained in McCoy’s 5a medium
supplemented with 2 mM L-glutamine and 10% FBS. All human cell lines used in
this study have been authenticated using the STR systems for cell line identification
(Promega, Madison, WI, USA) by a commercial vendor (www.DNAcenter.com) in
August 2012. Wild-type and p65− /− MEFs were maintained in DMEM with 10%
FBS and were generous gift from Dr. Alex Hoffman (University of California, San
Diego, CA, USA) and have been described.54
Antibodies and western blotting analysis. Antibodies against CtBP1
(cat. no. 07-306), H3K36me3 (cat. no. CS204368), H3K9me3 (cat. no. 07-523),
Acetyl H3 (cat. no. 06-599), H3K27me3 (cat. no. CS200603), H4K8 acetyl (cat. no.
06-760-MN), H4K20me1 (cat. no. 07-1570), H4K20me3 (cat. no. 07-463), H4 (cat.
no. 07-108) and NSD1 (cat. no. 04-1565) were purchased from Upstate
Biotechnology/Millipore (Billerica, MA, USA). Antibodies against EZH2 (cat. no.
4905) and HDAC-1 (cat. no. 2062) were purchased from Cell Signaling
Technologies (Danvers, MA, USA). BIM (cat. no. 202000) antibody was purchased
from Calbiochem/Millipore (Billerica, MA, USA), whereas p21 (cat. no. sc-756)
and PARP-1 (cat. no. sc-7150) antibodies were purchased from Santa Cruz
Biotechnologies (Santa Cruz, CA, USA). SETD2 antibody (PA5-34934) was
purchased from ThermoFisher Scientific (Waltham, MA, USA). Western blotting was
performed as described previously,39 and representative western blots from three or
more experiments are shown. Although primary antibodies in non-histone blots were
incubated in Tris-buffered saline-Tween 20 (TBS-T) with 5% non-fat milk power,
histone blots with few of the primary antibodies were incubated in 5% BSA
containing TBS-T.
siRNA transfection. Cells were seeded in MEM plus 10% FBS for 48 h and
then transfected with 25 nM of siRNA (Dharmacon, Lafayette, CO, USA) using
lipofectamine reagent. Cells were treated after 3 days of siRNA transfection with
DMAPT and harvested for proteins or RNA after 24 h of DMAPT treatment.
Quantitative reverse transcription-PCR (qRT-PCR). Independent
samples of total RNA were prepared using RNAeasy kit (Qiagen, Valencia, CA,
USA). First-strand cDNA was synthesized using random hexamers and superscript
II reverse transcriptase (Invitrogen, Carlsbad, CA, USA). qRT-PCR was performed
using the SYBR green according to the manufacturer’s protocol (Applied
Biosystems, Foster City, CA, USA). Expression of β-actin housekeeping gene
was used as an internal control for normalization between samples. Results
presented are from three or more experiments, and average± S.E.M. are
presented. Primer sequences used for qRT-PCR are provided in Supplementary
Table S1.
Apoptosis assay. Apoptosis was measured using Annexin V labeling using
the Apoptosis Assay Kit from Invitrogen, and the number of apoptotic cells after 24 h
of DMAPT treatment was measured by flow cytometry. Both floating and adherent
cells were collected and stained with Alexa Fluor-488-conjugated Annexin V and
propidium iodide. Annexin V-positive cells are apoptotic, propidium iodide-positive
cells are necrotic and double-positive cells are necroapoptotic.
Histone extraction. Cells were lysed with Triton Extraction Buffer (TEB: PBS
containing 0.5% Triton X 100(v/v), 2 mM phenylmethylsulfonylfluoride (PMSF),
0.02% (w/v) NaN3) and centrifuged at 6500 × g for 10 min at 4 °C to collect nuclei.
The histones were subsequently extracted with 0.2 M HCl (Abcam histone extraction
protocol, Cambridge, MA, USA).
Electrophoretic mobility gel shift assay. MDA-MB-231 and MEF cells
were harvested in their exponential growth phase with or without TNFα (5 ng/ml,
R&D Systems, Minneapolis, MN, USA) treatment for 15 min and assayed for NF-κB
and SP-1 (as a control) DNA-binding activity as described previously.39 Antibodies
for supershift assays were purchased from Santa Cruz (c-Rel, cat. no. sc-070) and
Millipore (p65, cat. no. 06-418; p50, cat. no. 06-886).
Statistical analysis. Results of qRT-PCR were analyzed using the GraphPad
software (www.Graphpad.com). Analysis of variance was used to determine the
P-values between mean measurements. A P-value ofo0.05 was deemed significant.
Analysis of public databases for prognostic relevance of NSD1
and SETD2. Expression array data of various bladder cancer stages were
obtained from NCBI GEO (GDS1479), and average± S.D. was calculated. NSD1
expression data were from a single affymetrix probe available in the data set,
whereas average from three probes was used for SETD2. For breast cancer,
analysis of TCGA data set55 for NSD1 and SETD2 expression is presented
although similar analysis using a public data set with gene expression pattern in
tumors of 1809 breast cancer patients yielded similar results.44
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